AnaptysBio reveals details of the 2014 Collaboration Agreement with Tesaro for the PD-1 antagonist dostarlimab, now Jemperli®.
Tesaro and GSK breached exclusivity and diligence provisions, leading to significant legal disputes.
AnaptysBio secured settlements but faces recurring breaches by Tesaro concerning clinical trials and commercialization efforts.
Collaboration Agreement Breach
Tesaro and GSK violated exclusivity and diligence clauses, resulting in a $60 million settlement with AnaptysBio.
Recurrent Breaches
Tesaro failed to disclose ongoing trials and focused on maximizing ADCs rather than optimizing dostarlimab's commercial potential.
Legal Consequences
Lawsuits and settlements highlight the challenges AnaptysBio faces in ensuring Tesaro's compliance with collaboration terms.
- The ongoing breaches raise concerns about Tesaro's commitment to fulfilling its obligations under collaboration agreements.
- AnaptysBio's efforts to secure settlements and amend the agreement indicate the company's proactive approach to protecting its rights and interests.
Despite settlements and amended terms, AnaptysBio continues to face challenges with Tesaro's repeated breaches, highlighting the complexities of collaboration agreements in the pharmaceutical industry.